GGrantIndex
← Search

Developmental

$330,609P30FY2013CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

The MCCC considers the Developmental Funds as one of the most critical components of CCSG support. Together with institutionally derived MCCC discretionary funds and the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, and the initiation of research projects or generation of pilot data for subsequent peer review grant applications. Given the small size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the last funding period, institutionally-derived MCCC discretionary funds and philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, and all funding for instrumentation and new laboratory set-up costs. Processes are firmly established in the MCCC to solicit and review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities and, in the case of shared resource development, the unambiguous need of peer review investigators. An increase in Developmental Funds is requested in this application, though it is commensurate with the funding level recommended for the current funding period (but not awarded). These Developmental Funds will be leveraged with institutionally derived MCCC discretionary funds. Funding is requested in the next project period to support initiatives in the following categories: ¿ Continued recruitment of outstanding new research faculty - the MCCC is currently actively recruiting to fill 20 positions across its three campuses ¿ Pilot projects - to enable the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ¿ Development of shared resources - to insure the scientific vitality of MCCC investigators and programs The MCCC's Developmental Fund request represents approximately 8% of the direct costs requested. The MCCC has a proven track record in stewardship of these funds as evidenced by the 'return on investment' of new faculty recruited to the center during the current grant period. The current request, substantially buttressed by the continued commitment of MCCC discretionary funds, will enable the Director to support activities critical to the sustained research excellence of this Cancer Center.

View original record on NIH RePORTER →